Lacerta Therapeutics is a clinical stage gene therapy company using a constellation of proprietary adeno-associated virus (AAV) vector technologies to develop treatments for central nervous system and lysosomal storage diseases. With unmatched scientific expertise and depth in the development, production, and application of AAV vectors, LacertaTherapeutics is advancing its clinical programs using its proprietary capsid variants and scalable vector manufacturing platform. The experience and accomplishments of the Lacerta Therapeutics founders are unsurpassed in AAV gene therapy. In addition to world-class basic AAV vector development and gene therapy clinical trial expertise, our team brings to bear individuals with novel insight into developing novel, targeted neurological and lysosomal storage disease treatments.

Biotechnology

Therapeutics

Lacerta Therapeutics

Barb Eppler

Venu Talla

John Spence

Megha Mahabole, MS, CTBS

Ryan M Spengler

Shannon Wilson

April Green

Fatima Shaerzadeh

The Leadership Team at Lacerta Therapeutics is responsible for guiding the company's strategic direction and ensuring operational excellence in gene therapy development. Comprising experts in quality assurance and scientific research, the team collaborates to optimize AAV vector technologies, drive clinical program advancements, and navigate regulatory landscapes, all while fostering innovation in treatments for central nervous system and lysosomal storage diseases.

Leadership Team

Research and Development

Leadership Team

About

Team members

Other teams at Lacerta Therapeutics

Research and Development